title: Erythroderma in two patients with psoriasis upon discontinuation of efalizumab treatment.
abstract: Efalizumab is therapeutically effective in moderate to severe plaque psoriasis. Rebound after discontinuing therapy affects approximately 14% of patients, while erythroderma occurs in less than 1% of the treated population. In this case report, we describe two non-responding patients with severe plaque psoriasis who developed erythroderma after treatment was ceased. Non-responders are more likely to suffer from rebound. This article emphasizes the importance of close monitoring of non-responders to efalizumab after discontinuance of treatment.
authors.affiliation: Department of Dermatology,, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. E.Kop@derma.umcn.nl
authors.forename: Else N
authors.initials: EN
authors.lastname: Kop
authors.forename: John E M
authors.initials: JE
authors.lastname: Körver
authors.forename: Delphine
authors.initials: D
authors.lastname: Van Ruysevelt
authors.forename: Elke M G J
authors.initials: EM
authors.lastname: De Jong
authors.forename: Pieter G
authors.initials: PG
authors.lastname: Van der Valk
authors.forename: Peter C M
authors.initials: PC
authors.lastname: Van de Kerkhof
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D003873:Dermatitis, Exfoliative / Q000209:etiology* / Q000503:physiopathology; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy*; D018570:Risk Assessment; D012720:Severity of Illness Index; D013375:Substance Withdrawal Syndrome / Q000209:etiology* / Q000503:physiopathology; D013997:Time Factors; D017211:Treatment Failure
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C472181:efalizumab